Jennison Associates’s Lifestance Health LFST Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$129M Buy
12,077,557
+1,848,756
+18% +$14.3M 0.08% 123
2026
Q1
$65.2M Buy
10,228,801
+2,843,388
+39% +$19.8M 0.04% 188
2025
Q4
$52M Sell
7,385,413
-47,857
-0.6% -$289K 0.03% 204
2025
Q3
$40.9M Buy
7,433,270
+168,021
+2% +$823K 0.02% 252
2025
Q2
$37.6M Sell
7,265,249
-989,987
-12% -$5.93M 0.02% 256
2025
Q1
$55M Buy
8,255,236
+168,856
+2% +$1.28M 0.04% 202
2024
Q4
$59.6M Buy
8,086,380
+5,949,438
+278% +$42.7M 0.04% 203
2024
Q3
$15M Buy
2,136,942
+184,896
+9% +$1.11M 0.01% 368
2024
Q2
$9.58M Buy
1,952,046
+13,723
+0.7% +$82.7K 0.01% 387
2024
Q1
$12M Buy
1,938,323
+12,629
+0.7% +$85.1K 0.01% 385
2023
Q4
$15.1M Sell
1,925,694
-120,664
-6% -$778K 0.01% 353
2023
Q3
$14.1M Buy
2,046,358
+535,358
+35% +$4.34M 0.01% 346
2023
Q2
$13.8M Buy
1,511,000
+837,726
+124% +$6.96M 0.01% 355
2023
Q1
$5M Buy
+673,274
New +$3.73M ﹤0.01% 440

Other funds holding LFST

Jennison Associates's LFST Position: Q2 2026 in Review

Jennison Associates increased its Lifestance Health (LFST) stake by 18% in Q2 2026, buying an estimated $14.3M and bringing the position to 12,077,557 shares worth $129M. The position accounts for 0.08% of the portfolio, ranked #123.

Jennison Associates first reported a position in LFST in Q1 2023 and has held it in 14 quarters since. 287 funds tracked by Wall St. Rank hold LFST as of Q2 2026.

  • Jennison Associates held 12,077,557 shares of Lifestance Health worth $129M as of Q2 2026.
  • Jennison Associates bought 1,848,756 Lifestance Health shares in Q2 2026, an estimated $14.3M.
  • Lifestance Health made up 0.08% of Jennison Associates's portfolio in Q2 2026, its #123 holding.
  • Jennison Associates first reported a position in Lifestance Health in Q1 2023 and has held it in 14 quarters since.
  • 287 funds tracked by Wall St. Rank held Lifestance Health as of Q2 2026.

Based on Jennison Associates's 13F filing for Q2 2026, filed 3 Aug 2026.